Inhibikase Therapeutics Inc expected to post a loss of 17  cents a share - Earnings Preview

Inhibikase Therapeutics

13/05/2022 22:25

* Inhibikase Therapeutics Inc  IKT.OQ   IKT.O  is expected
to show
a fall in quarterly revenue when it reports  results on May 16. 
    * The Atlanta Georgia-based  company is expected to report 
a
78.7% decrease in revenue to $300 thousand from $1.41 million a
year ago, according to the estimate from one analyst, based on
Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Inhibikase
Therapeutics
Inc is for a loss of 17 cents per share. 
    * The one available analyst rating on the shares is "buy".  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Inhibikase
Therapeutics Inc is $6​, above​ its last closing price of $0.68.
​​​

This summary was machine generated May 13 at 21:25 GMT.  All
figures in US dollars  unless otherwise stated